HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Translational Medicine

Background:

• The traditional hypothesis linking high HDL cholesterol (HDL-C) to cardiovascular protection is challenged by recent clinical trial outcomes.
• Extensive preclinical evidence supports the vascular protective role of apolipoprotein A-1 (ApoA-1) and HDL-like particles.

Purpose of the Study:

• To review current strategies for leveraging the cardiovascular benefits of HDL/ApoA-1.
• To evaluate HDL infusion therapy and gene transfer as potential therapeutic approaches.

Main Methods:

• Review of preclinical data and clinical trial results for HDL/ApoA-1-based therapies.
• Analysis of studies involving CETP inhibitors, niacin, HDL infusion, and gene transfer.

Main Results:

• While some CETP inhibitors and niacin failed to show benefits, preclinical data consistently support ApoA-1's protective effects.
• Small clinical trials of HDL/ApoA-1 infusion therapy show encouraging results.
• Preclinical studies of gene transfer for HDL/ApoA-1 also indicate potential benefits.

Conclusions:

• Despite recent setbacks with HDL-C-raising drugs, HDL/ApoA-1 therapies, particularly infusion and gene transfer, warrant further investigation.
• Large-scale clinical trials are necessary to definitively establish the efficacy of these HDL/ApoA-1-based strategies for cardiovascular disease prevention.